Balchem Corporation (BCPC) - 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This report covers the fiscal year ended December 31, 2006. Balchem Corporation develops, manufactures, and markets specialty performance ingredients for the food, nutritional, feed, pharmaceutical, and medical sterilization industries. The Company operates through three segments: Specialty Products (ethylene oxide sterilants and fumigants), Encapsulated/Nutritional Products (microencapsulation and chelation solutions), and BCP Ingredients (choline chloride for animal feed).
Key Financial Metrics (2006)
| Metric | 2006 | 2005 |
|---|---|---|
| Net Sales | $100.9 million | $83.1 million |
| Gross Margin | $34.0 million (33.7%) | $28.7 million (34.5%) |
| Net Earnings | $12.3 million | $11.0 million |
| Diluted EPS | $0.67 | $0.61 |
| Operating Cash Flow | $16.4 million | $13.7 million |
| Capital Expenditures | $2.3 million | $1.8 million |
| Total Assets | $92.3 million | $75.1 million |
| Long-Term Debt | $0 | $0 |
| Cash & Equivalents | $5.2 million | $13.0 million |
Note: All figures in millions unless otherwise noted. EPS and share data adjusted for 3-for-2 stock splits in 2005 and 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21.4% to $100.9 million, driven by volume growth and acquisitions. The Encapsulated/Nutritional segment grew 27.9% and BCP Ingredients grew 29.1%.
- Acquisitions: Significant growth was fueled by the February 2006 acquisition of Chelated Minerals Corporation (CMC) and the August 2006 acquisition of a choline chloride facility in St. Gabriel, Louisiana.
- Margin Compression: Gross margin percentage declined slightly from 34.5% to 33.7% due to higher raw material and energy costs and unfavorable product mix in the pharmaceutical line.
- Operating Expenses: Increased 26.0% to $14.8 million, primarily due to the adoption of SFAS 123R (stock-based compensation expense of $0.98 million), increased payroll, and amortization from the CMC acquisition.
- Liquidity: Cash and cash equivalents decreased by $7.8 million to $5.2 million, largely due to $22.9 million in cash paid for acquisitions.
Outlook, Risks, and Management Commentary
- Capital Projects: Capital expenditures are projected to be approximately $4.8 million for 2007.
- Regulatory Risks (Ethylene Oxide): The EPA is re-registering ethylene oxide. A 2006 decision prohibits its use on basil effective August 2007 but allows use on other spices. The EPA is assessing carcinogenicity, with a final decision expected in 2007. Management believes the product has no equally effective substitute for medical sterilization.
- Customer Concentration: One customer in the specialty products segment accounted for approximately 8% of net sales in 2006. Loss of this customer could materially impact results.
- Legal Proceedings: The Company was dismissed from a significant product liability lawsuit (Casey Liesse v. AGA AB) regarding ethylene oxide exposure; the appeal was dismissed in October 2006.
- Environmental: The Verona, Missouri facility is a designated Superfund site, but remediation is considered complete, and the Company is indemnified by the prior owner.
Investor Verification Checklist
- EPA Re-registration Status: Verify the final outcome of the EPA's Re-registration Eligibility Decision (RED) for ethylene oxide and any potential restrictions on medical sterilization or spice fumigation uses.
- Acquisition Integration: Assess the operational performance and revenue contribution of the CMC and St. Gabriel acquisitions in 2007.
- Raw Material Costs: Monitor trends in raw material and energy prices to determine if margin compression continues or if price increases can be passed to customers.
- Customer Concentration: Confirm the stability of the relationship with the single customer representing 8% of sales.
- Stock-Based Compensation: Review the impact of SFAS 123R adoption on future earnings, as this represents a recurring non-cash expense not present in prior years.